Eli Lilly Raises Forecasts as Obesity Drug Sales Surge, Outpacing Novo Nordisk

Eli Lilly has significantly raised its revenue and profit outlook for 2026, driven by soaring demand for its obesity drugs Mounjaro and Zepbound, which are widening its lead over competitor Novo Nordisk. This surge in sales highlights the booming market for GLP-1 weight-loss medications.

5 Aug, 11:45 — 5 Aug, 21:00

Post Share

Why this matters

The surge in demand for obesity drugs is reshaping the pharmaceutical landscape, creating a highly lucrative market. Eli Lilly's outperformance signifies a major shift in market leadership, impacting investor confidence and potentially influencing future drug development and healthcare strategies globally.

Key entitiesEli Lilly & Co.Novo Nordisk Mounjaro Zepbound GLP-1

The Story

What 11 sources agree on, dispute, and miss

What sources agree on

Eli Lilly raised its 2026 revenue forecast to $85-87 billion.
Eli Lilly's obesity drugs Mounjaro and Zepbound are driving its revenue growth.
Novo Nordisk also raised its annual sales and operating profit forecast.
Demand for weight-loss drugs is soaring.

Key claims1 agreed · 2 unverified

✓

Eli Lilly expects 2026 revenue of $85-87 billion.

agreed·politiken

Eli Lilly's Mounjaro sales doubled this year.

unverified·The Independent

Novo Nordisk's sales of its weight-loss pill disappointed investors.

unverified·capital-bg

Where they diverge

Market leadership in the GLP-1 obesity drug sector

marketwatchYahooseeking-alpha

Eli Lilly has outmaneuvered Novo Nordisk and taken control of the diet-drug market, unseating its lead.

FTpolitikencapital-bgberlingske

Eli Lilly is a strong competitor, but Novo Nordisk also raised forecasts, indicating continued strong performance, though its stock fell.

Investor reaction to company performance

cnbczerohedgeforbesThe Independent

Eli Lilly's stock is rising due to its strong performance and raised outlook.

FTcapital-bg

Novo Nordisk's shares fell despite raising forecasts, due to investor concerns about over-reliance on obesity treatments and disappointing sales of its weight-loss pill.

Coverage gaps

Specific details on Novo Nordisk's half-year results and clinical results for new medications.

Reportedcapital-bgberlingske

Missingforbescnbcseeking-alpha+6

Discussion of a cannabis-derived drug for PTSD and Apnimed’s IPO.

Reportedforbes

Missingcnbcseeking-alphamarketwatch+7

The Story

Analyzing sources…

Source Diversity

Excellent (83/100)

11 sources33/33

Spectrum spread— 5/5 buckets covered33/33

Far L1

Far Left (1)

The Independent

Left3

Left (3)

cnbcpolitikenYahoo

Center3

Center (3)

forbesmarketwatchFT

Right3

Right (3)

seeking-alphacapital-bgberlingske

Far R1

Far Right (1)

zerohedge

Geographic diversity— 4 regions17/34

US6Denmark2UK2Bulgaria1

Political spectrum

LeftCenterRight

independent

politiken

cnbc

yahoo

forbes

marketwatch

seeking-alpha

capital-bg

berlingske

zerohedge

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

The Independentcenter-leftleftneutralMostly FactualReports on sales figures and drug boom prevalence

politikencenter-leftcenter-leftneutralMostly FactualReports on financial figures and company expectations

Coverage leans: center

The coverage is largely centered, focusing on financial performance and market competition in the pharmaceutical industry, with some outlets highlighting the broader economic implications.

Sources

Showing 7 of 11 sources

FTVery High1d ago

Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars

Drugmakers’ share prices diverge as investors take dim view of Novo’s over-reliance on obesity treatments

Read full article →

cnbcMostly Factual1d ago

We're increasing our Eli Lilly price target after another beat-and-raise quarter

The strength of its GLP-1 business suggests the stock still has more room to run.

Read full article →

marketwatchMostly Factual1d ago

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

By Jaimy Lee

Read full article →

forbes1d ago

Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more

By Alex Knapp, Forbes Staff

Read full article →

The IndependentMostly Factual1d ago

Mounjaro sales double this year as obesity drug boom prevails, says maker

The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.

By Anna Wise

Read full article →

seeking-alphaMixed1d ago

Lilly outperforms in bid to unseat Novo’s lead in oral GLP-1 market

Read full article →

zerohedgeLow1d ago

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand Shares of Eli Lilly & Co. are rising in premarket trading after the pharmaceutical giant raised its full-year revenue forecast following a 48% jump in second-quarter sales, fueled by accelerating demand for the diabetes drug Mounjaro and the obesity treatment Zepbound. Lilly's second-quarter results topped Wall Street expectations: Adjusted earnings rose to $8.38 a share from $6.31 a year ear...

By Tyler Durden

Read full article →

Coverage Timeline

First report: berlingske · 5 Aug, 11:14|Full coverage: 11 · 10h|Window: 10h

Left-leaningCenterRight-leaning

berlingske5 Aug, 11:14First to report

Novo-konkurrents omsætning banker op – slår forventninger markant og opjusterer

capital-bg5 Aug, 11:37

Продажбите на хапчето за отслабване на Novo Nordisk разочароваха инвеститорите

zerohedge5 Aug, 11:45

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

The Independent5 Aug, 12:37

Mounjaro sales double this year as obesity drug boom prevails, says maker

FT5 Aug, 12:40

Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars

1h later

Yahoo5 Aug, 13:55

Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk

1h later

politiken5 Aug, 14:59

Novo Nordisk-rival løfter sine forventninger til 2026

2h later

marketwatch5 Aug, 16:52

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

2h later

seeking-alpha5 Aug, 18:48

Lilly outperforms in bid to unseat Novo’s lead in oral GLP-1 market

cnbc5 Aug, 19:28

We're increasing our Eli Lilly price target after another beat-and-raise quarter

2h later

forbes5 Aug, 21:00Latest update

Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

Story evolution

The initial narrative focused on Eli Lilly's strong individual performance, which then evolved to highlight its competitive advantage over Novo Nordisk and the broader implications for the obesity drug market and investor confidence.

Lilly's Strong Earnings ReportAug 5 morning

Eli Lilly releases its Q2 earnings, significantly raising its 2026 revenue forecasts due to strong obesity drug sales.

Market Reaction and ComparisonAug 5 midday

Outlets report on Lilly's stock jump and compare its performance to Novo Nordisk, noting a divergence in investor sentiment despite both raising forecasts.

Analysis of Market ShiftAug 5 afternoon

Deeper analysis emerges, suggesting Lilly has outmaneuvered Novo Nordisk in the GLP-1 market and discussing broader economic implications.

Eli Lilly Raises Forecasts as Obesity Drug Sales Surge, Outpacing Novo Nordisk

Why this matters

The Story

What sources agree on

Key claims1 agreed · 2 unverified

Where they diverge

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars

We're increasing our Eli Lilly price target after another beat-and-raise quarter

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

Mounjaro sales double this year as obesity drug boom prevails, says maker

Lilly outperforms in bid to unseat Novo’s lead in oral GLP-1 market

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

Coverage Timeline

Novo-konkurrents omsætning banker op – slår forventninger markant og opjusterer

Продажбите на хапчето за отслабване на Novo Nordisk разочароваха инвеститорите

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

Mounjaro sales double this year as obesity drug boom prevails, says maker

Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars

Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk

Novo Nordisk-rival løfter sine forventninger til 2026

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Lilly outperforms in bid to unseat Novo’s lead in oral GLP-1 market

We're increasing our Eli Lilly price target after another beat-and-raise quarter

Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

Story evolution

Related Stories

Vodafone and Orange Begin Satellite-to-Smartphone Tests in Romania

Lamda Development Stock Stagnates Below Pre-War Levels

Swedish Apartment Prices Fell in July, Turnaround Expected

Greek Hotels Launch "Lexicon of Greek Hospitality" Project

Why this matters

Story evolution

The Story

What sources agree on

Key claims1 agreed · 2 unverified

Where they diverge

Coverage gaps

Political spectrum

Coverage matrix(11 sources)